The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

April 30, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On March 28, the U.S. Food and Drug Administration (FDA) approved certolizumab pegol (Cimzia) for a new indication: the treatment of adults with active non-radiographic axial spondyloarthritis (SpA) with objective signs of inflammation.1 This approval makes certolizumab pegol the first and only FDA-approved drug for this disease.2 The treatment is already FDA approved for treating ankylosing spondylitis (AS), rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and Crohn’s disease.

You Might Also Like
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
Also By This Author
  • Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment

The recommended certolizumab pegol dose in adults with non-radiographic axial SpA is 400 mg, initially given as two subcutaneous injections of 200 mg, and at Weeks 2 and 4. These initial doses should be followed by 200 mg given every two weeks or 400 mg given every four weeks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background
The approval was based on data from a phase 3, double-blind, placebo-controlled, 52-week study known as C-AXSPAND. C-AXSPAND included adult patients with active axial SpA but without x-ray evidence of AS.2

To participate, patients needed to have objective evidence of inflammatory disease, defined as sacroiliitis on MRI and/or elevated C-reactive protein levels. Patients also had to have had an inadequate response to, have a contraindication to, or be intolerant to at least two non-steroidal anti-inflammatory drugs (NSAIDs). Inadequate response to an NSAID was defined as a lack of response after at least 14 days of continuous NSAID therapy at the highest tolerated dose. Patients in both the treatment and placebo groups remained on their background therapies, which included NSAIDs, corticosteroids, analgesics and/or slow-acting anti-rheumatic drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The study randomized patients (N=317) to receive certolizumab pegol or placebo. The primary endpoint was improvement of the Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) at Week 52, which was met. Ankylosing Spondylitis Assessment Score (ASAS40), an important secondary endpoint, was also met at Week 12.

The ASDAS-MI score was achieved by 47% of certolizumab pegol-treated patients compared with 7% of placebo-treated patients. In the certolizumab pegol-treated patients, 48% achieved ASAS40, while only 11% of placebo-treated patients attained ASAS40. During the study, no new safety signals were identified.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Department of Health & Human Services. FDA supplemental approval letter for Cimzia. 2019 Mar 28.
  2. UCB Inc. News release: Cimzia (certolizumab pegol) is now the first and only U.S. FDA-approved treatment for non-radiographic axial spondyloarthritis. 2019 Mar 28.

Filed Under: Drug Updates Tagged With: axial spondyloarthritis (SpA), Certolizumab Pegol, FDA, non-radiographic axial spondyloarthritis, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)